With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots
Debut deal for $300M fund brings in royalty streams for Paratek’s Nuzyra
CBC Group believes the maturing market for innovative products in Greater China represents an opportunity sufficient to support its launch of R-Bridge, the first discrete fund dedicated to non-dilutive investments in royalty streams and credit facilities for life sciences companies doing business in Asia.
The $300 million vehicle revealed its first investment Monday, a $60 million deal that includes full local royalty rights for Nuzyra omadacycline, an FDA-approved anti-infective drug developed by Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). Zai Lab Ltd. (NASDAQ:ZLAB) holds Nuzyra’s rights in China, where it is under regulatory review to treat acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP)...